Novo Nordisk ADR [NVO] stock is trading at $90.59, up 2.85%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NVO shares have gain 16.33% over the last week, with a monthly amount glided 11.70%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Bernstein upgraded its rating to Mkt Perform on January 06, 2025. On May 30, 2024, Goldman initiated with a Buy rating and assigned a price target of $156 on the stock. BMO Capital Markets started tracking the stock assigning a Outperform rating and suggested a price target of $163 on April 12, 2024. Morgan Stanley initiated its recommendation with a Overweight and recommended $120 as its price target on January 23, 2024. In a note dated December 01, 2023, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $120 on this stock.
Novo Nordisk ADR [NVO] stock has fluctuated between $77.82 and $148.15 over the past year. Currently, Wall Street analysts expect the stock to reach $158 within the next 12 months. Novo Nordisk ADR [NYSE: NVO] shares were valued at $90.59 at the most recent close of the market. An investor can expect a potential return of 74.41% based on the average NVO price forecast.
Analyzing the NVO fundamentals
Novo Nordisk ADR [NYSE:NVO] reported sales of 42.09B for the trailing twelve months, which represents a growth of 29.02%. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at 0.44%, Pretax Profit Margin comes in at 0.44%, and Net Profit Margin reading is 0.35%. To continue investigating profitability, this company’s Return on Assets is posted at 0.22, Equity is 0.85 and Total Capital is 0.52. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.72.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 88.77 points at the first support level, and at 86.94 for the second support level. However, for the 1st resistance point, the stock is sitting at 91.77, and for the 2nd resistance point, it is at 92.95.
Ratios To Look Out For
For context, Novo Nordisk ADR’s Current Ratio is 0.74. Also, the Quick Ratio is 0.55, while the Cash Ratio stands at 0.07. Considering the valuation of this stock, the price to sales ratio is 7.24, the price to book ratio is 20.19 and price to earnings (TTM) ratio is 27.60.
